Valuation: Virbac

Market Cap 2.62B 2.94B 2.45B 2.22B 4.18B 284B 4.22B 29.39B 11.43B 145B 11.05B 10.81B 466B P/E 2026 *
15.1x
P/E 2027 * 13.6x
Enterprise Value 2.74B 3.08B 2.56B 2.32B 4.38B 297B 4.41B 30.77B 11.97B 152B 11.57B 11.32B 487B EV / Sales 2026 *
1.77x
EV / Sales 2027 * 1.62x
Free-Float
49.03%
Yield 2026 *
0.55%
Yield 2027 * 0.65%
1 day+1.63%
1 week+1.46%
Current month+0.16%
1 month-2.19%
3 months-6.02%
6 months-11.11%
Current year-12.73%
1 week 301.5
Extreme 301.5
316
1 month 297
Extreme 297
319.5
Current year 297
Extreme 297
389.5
1 year 297
Extreme 297
389.5
3 years 249.7
Extreme 249.7
400
5 years 215
Extreme 215
448.5
10 years 102.1
Extreme 102.1
448.5
Manager TitleAgeSince
Chief Executive Officer 46 2025-08-31
Chief Executive Officer 50 2024-09-26
Chief Operating Officer 64 2021-12-31
Director TitleAgeSince
Chairman 61 2006-03-31
Director/Board Member 68 2010-07-27
Director/Board Member 65 2017-09-04
Date Insider Type Main position Quantity % Market Cap. Importance
4/22/24 Sell

Chief Executive Officer

810 0.0096%
4/22/24 Sell

Chief Executive Officer

140 0.0017%
4/22/24 Sell

Chief Executive Officer

1,688 0.0200%
Change 5-day change 1-year change 3-year change Capi.($)
+1.63%+1.46%-3.41%+21.17% 2.88B
+1.26%-2.30%+37.82%+113.76% 1,019B
+0.73%-6.31%+35.06%+62.14% 610B
+0.35%+0.15%+14.01%+80.87% 470B
+1.72%-4.54%+59.14%+37.01% 344B
+0.26%-1.58%+21.97%+41.79% 336B
+0.60%-3.48%+11.37%+34.33% 266B
+1.65%-4.27%-5.47%+9.69% 241B
-0.09%-3.71%+35.15%+51.88% 218B
-0.28%-5.24%+27.99%+93.08% 179B
Average +0.33%-3.28%+23.36%+54.57% 368.57B
Weighted average by Cap. +0.16%-3.50%+29.46%+70.02%

Financials

2026 *2027 *
Net sales 1.55B 1.74B 1.45B 1.31B 2.47B 168B 2.5B 17.39B 6.76B 85.64B 6.54B 6.4B 275B 1.64B 1.85B 1.54B 1.39B 2.63B 178B 2.65B 18.48B 7.19B 91.01B 6.95B 6.8B 293B
Net income 174M 196M 163M 148M 278M 18.87B 280M 1.95B 760M 9.62B 735M 719M 30.96B 194M 218M 181M 164M 310M 21.02B 312M 2.18B 847M 10.72B 819M 801M 34.49B
Net Debt 122M 138M 115M 104M 196M 13.28B 197M 1.38B 535M 6.77B 517M 506M 21.79B 44.72M 50.35M 41.87M 37.94M 71.53M 4.85B 72.11M 503M 196M 2.48B 189M 185M 7.96B
Projected Income Statement - Annual - Virbac
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Date Price Change Volume
26-10-06 €312.00 +1.63% 2,829
26-10-05 €307.00 -0.32% 6,382
26-10-02 €308.00 +0.49% 5,533
26-10-01 €306.50 -1.61% 11,691
26-09-30 €311.50 +0.32% 20,087
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - Virbac
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
312.00EUR
Average target price
412.75EUR
Spread / Average Target
+32.29%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Virbac
  1. Stock Market
  2. Stocks
  3. VIRP Stock